Sirius Therapeutics Completes Enrollment in Phase 1 Trial of SRSD107, a First-in-Class siRNA Being Developed for Anticoagulant

July 11,2024, SAN DIEGO, CA & SHANGHAI - Sirius Therapeutics announces that the company has completed enrollment of all participants in the Phase I study of SRSD107, its novel siRNA therapeutic agent, targeting coagulation Factor XI (FXI) for the prevention and treatment of thromboembolic disorders. The Phase 1 study is being conducted in Australia and China, in which preliminary data have demonstrated a favorable safety and tolerability profile.

“Successful enrollment of the Phase 1 study, while only a preliminary step, is an important milestone for the SRSD107 clinical development program,” said Patrick Yue, CMO of Sirius Therapeutics. “The data generated from this study will provide key insights into the PK and PD of SRSD107 and allow us to optimize its use for the patients that will ultimately benefit from it.”

About Thromboembolic Disorders

Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide¹.

About SRSD107

SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.

About Sirius Therapeutics

Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapies for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced programs are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the US and a translational center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital and the leadership team. Learn more at www.siriusrna.com.

[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128